Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

Daniel J. Lovell, Andreas Reiff, Norman Todd Ilowite, Carol A. Wallace, Yun Chon, Shao Lee Lin, Scott W. Baumgartner, Edward H. Giannini

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Objective. To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Methods. Patients with JRA who previously participated in a randomized controlled trial (RCT) of etanercept were eligible to receive etanercept in a long-term open-label extension (OLE) trial. Safety end points included the incidences of serious adverse events (SAEs), medically important infections (MIIs), and death. Efficacy end points included the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, Pedi 70, Pedi 90, and Pedi 100 criteria for improvement. Results. Of the 69 patients originally enrolled in the RCT, 58 (84%) participated in the OLE, for a total of 318 patient-years of etanercept exposure. A total of 42 of the 58 patients (72%) entered the fourth year of continuous etanercept treatment, and 26 patients (45%) entered the eighth year. Sixteen patients (23% of those entering the RCT) reported 39 SAEs. The overall rate of SAEs (0.12 per patient-year) did not increase with long-term exposure to etanercept. The rate of MIIs (0.03 per patient-year) remained low; 1 new MII was reported in patients with ≥5 years of etanercept exposure. No cases of tuberculosis, opportunistic infections, malignancies, lymphomas, lupus, demyelinating disorders, or deaths were reported. An ACR Pedi 70 response or higher was achieved by 100% of patients with 8 years of data (11 of 11) and by 61% of patients according to the last observation carried forward data (28 of 46). Conclusion. These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients. Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.

Original languageEnglish (US)
Pages (from-to)1496-1504
Number of pages9
JournalArthritis and Rheumatism
Volume58
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Juvenile Arthritis
Safety
Therapeutics
Randomized Controlled Trials
Etanercept
Infection
Opportunistic Infections
Rheumatology
Demyelinating Diseases
Signs and Symptoms
Lymphoma
Tuberculosis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Lovell, D. J., Reiff, A., Ilowite, N. T., Wallace, C. A., Chon, Y., Lin, S. L., ... Giannini, E. H. (2008). Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism, 58(5), 1496-1504. https://doi.org/10.1002/art.23427

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. / Lovell, Daniel J.; Reiff, Andreas; Ilowite, Norman Todd; Wallace, Carol A.; Chon, Yun; Lin, Shao Lee; Baumgartner, Scott W.; Giannini, Edward H.

In: Arthritis and Rheumatism, Vol. 58, No. 5, 05.2008, p. 1496-1504.

Research output: Contribution to journalArticle

Lovell, DJ, Reiff, A, Ilowite, NT, Wallace, CA, Chon, Y, Lin, SL, Baumgartner, SW & Giannini, EH 2008, 'Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis', Arthritis and Rheumatism, vol. 58, no. 5, pp. 1496-1504. https://doi.org/10.1002/art.23427
Lovell, Daniel J. ; Reiff, Andreas ; Ilowite, Norman Todd ; Wallace, Carol A. ; Chon, Yun ; Lin, Shao Lee ; Baumgartner, Scott W. ; Giannini, Edward H. / Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. In: Arthritis and Rheumatism. 2008 ; Vol. 58, No. 5. pp. 1496-1504.
@article{1de2ccc1075d437c8f9b232ab9f28aa9,
title = "Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis",
abstract = "Objective. To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Methods. Patients with JRA who previously participated in a randomized controlled trial (RCT) of etanercept were eligible to receive etanercept in a long-term open-label extension (OLE) trial. Safety end points included the incidences of serious adverse events (SAEs), medically important infections (MIIs), and death. Efficacy end points included the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, Pedi 70, Pedi 90, and Pedi 100 criteria for improvement. Results. Of the 69 patients originally enrolled in the RCT, 58 (84{\%}) participated in the OLE, for a total of 318 patient-years of etanercept exposure. A total of 42 of the 58 patients (72{\%}) entered the fourth year of continuous etanercept treatment, and 26 patients (45{\%}) entered the eighth year. Sixteen patients (23{\%} of those entering the RCT) reported 39 SAEs. The overall rate of SAEs (0.12 per patient-year) did not increase with long-term exposure to etanercept. The rate of MIIs (0.03 per patient-year) remained low; 1 new MII was reported in patients with ≥5 years of etanercept exposure. No cases of tuberculosis, opportunistic infections, malignancies, lymphomas, lupus, demyelinating disorders, or deaths were reported. An ACR Pedi 70 response or higher was achieved by 100{\%} of patients with 8 years of data (11 of 11) and by 61{\%} of patients according to the last observation carried forward data (28 of 46). Conclusion. These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients. Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.",
author = "Lovell, {Daniel J.} and Andreas Reiff and Ilowite, {Norman Todd} and Wallace, {Carol A.} and Yun Chon and Lin, {Shao Lee} and Baumgartner, {Scott W.} and Giannini, {Edward H.}",
year = "2008",
month = "5",
doi = "10.1002/art.23427",
language = "English (US)",
volume = "58",
pages = "1496--1504",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

AU - Lovell, Daniel J.

AU - Reiff, Andreas

AU - Ilowite, Norman Todd

AU - Wallace, Carol A.

AU - Chon, Yun

AU - Lin, Shao Lee

AU - Baumgartner, Scott W.

AU - Giannini, Edward H.

PY - 2008/5

Y1 - 2008/5

N2 - Objective. To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Methods. Patients with JRA who previously participated in a randomized controlled trial (RCT) of etanercept were eligible to receive etanercept in a long-term open-label extension (OLE) trial. Safety end points included the incidences of serious adverse events (SAEs), medically important infections (MIIs), and death. Efficacy end points included the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, Pedi 70, Pedi 90, and Pedi 100 criteria for improvement. Results. Of the 69 patients originally enrolled in the RCT, 58 (84%) participated in the OLE, for a total of 318 patient-years of etanercept exposure. A total of 42 of the 58 patients (72%) entered the fourth year of continuous etanercept treatment, and 26 patients (45%) entered the eighth year. Sixteen patients (23% of those entering the RCT) reported 39 SAEs. The overall rate of SAEs (0.12 per patient-year) did not increase with long-term exposure to etanercept. The rate of MIIs (0.03 per patient-year) remained low; 1 new MII was reported in patients with ≥5 years of etanercept exposure. No cases of tuberculosis, opportunistic infections, malignancies, lymphomas, lupus, demyelinating disorders, or deaths were reported. An ACR Pedi 70 response or higher was achieved by 100% of patients with 8 years of data (11 of 11) and by 61% of patients according to the last observation carried forward data (28 of 46). Conclusion. These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients. Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.

AB - Objective. To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Methods. Patients with JRA who previously participated in a randomized controlled trial (RCT) of etanercept were eligible to receive etanercept in a long-term open-label extension (OLE) trial. Safety end points included the incidences of serious adverse events (SAEs), medically important infections (MIIs), and death. Efficacy end points included the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, Pedi 70, Pedi 90, and Pedi 100 criteria for improvement. Results. Of the 69 patients originally enrolled in the RCT, 58 (84%) participated in the OLE, for a total of 318 patient-years of etanercept exposure. A total of 42 of the 58 patients (72%) entered the fourth year of continuous etanercept treatment, and 26 patients (45%) entered the eighth year. Sixteen patients (23% of those entering the RCT) reported 39 SAEs. The overall rate of SAEs (0.12 per patient-year) did not increase with long-term exposure to etanercept. The rate of MIIs (0.03 per patient-year) remained low; 1 new MII was reported in patients with ≥5 years of etanercept exposure. No cases of tuberculosis, opportunistic infections, malignancies, lymphomas, lupus, demyelinating disorders, or deaths were reported. An ACR Pedi 70 response or higher was achieved by 100% of patients with 8 years of data (11 of 11) and by 61% of patients according to the last observation carried forward data (28 of 46). Conclusion. These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients. Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.

UR - http://www.scopus.com/inward/record.url?scp=43949143169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949143169&partnerID=8YFLogxK

U2 - 10.1002/art.23427

DO - 10.1002/art.23427

M3 - Article

C2 - 18438876

AN - SCOPUS:43949143169

VL - 58

SP - 1496

EP - 1504

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -